There is no longer a diagnosis of acute aplastic anemia. Aplastic anemia is divided into non-severe aplastic anemia and severe aplastic anemia, and the treatment of this disease is mainly supportive therapy as well as etiological treatment. 1. Supportive therapy refers to the transfusion of blood products such as red blood cells and platelets, prevention and control of infections, and medications including levofloxacin. 2. Etiological treatment means that once aplastic anemia is diagnosed, the severity of the disease should be clarified and treated as early as possible. (1) Patients with severe remittent anemia age >35 years old or age ≤35 years old but without HLA compatible sibling donor, preferred immunosuppressive treatment with ATG/ALG and cyclosporine. (2) HLA-conjugate hematopoietic stem cell transplantation from HLA-conjugate sibling donors is preferred for severe remodeling in those who are ≤35 years of age and have an HLA-conjugate sibling donor. (3) Transfusion-dependent non-severe cataracts can be treated with cyclosporine combined with pro-hematopoietic (testosterone undecanoate, etc.) therapy, and if the treatment is ineffective for 6 months, then it will be treated as severe cataracts. (4) Non-transfusion-dependent non-severe cataracts can be treated with cyclosporine and/or hematopoietic (testosterone undecanoate, etc.) therapy. Specific treatment should be carried out under the supervision of physicians.